Skip to main content
SpringerLink
Log in

Formulations of Extemporaneous Intraocular Injections

  • Chapter
  • First Online:
Extemporaneous Ophthalmic Preparations

  • 1128 Accesses

Abstract

In the following, the most common 15 formulations are presented and discussed following a systematic methodology starting with the composition and drug family, followed by use, dose, and preparation. The preparation is discussed in detail in terms of concentration(s), procedure, expiration date, storage, packaging, and special precautions. Some formulations are hazardous; therefore, special caution is highlighted so that the medication must be prepared in compliance with the United States Pharmacopeia (USP) <800>.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Change history

  • 10 October 2023

    A correction has been published.

References

  1. Trissel LA. Trissel’s stability of compounded formulations. 4th ed. Washington DC: American Pharmacists Association; 2009. p. 26–7.

    Google Scholar 

  2. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy. 2007;27(3):369–88.

    Article  CAS  PubMed  Google Scholar 

  3. Trissel LA, Trissel LA. Handbook on injectable drugs. Bethesda: American Society of Health-System Pharmacists; 2011. p. 613.

    Google Scholar 

  4. Bae JH, Lee SC. Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis. Japan J Ophthalmol. 2015;59(5):346–52.

    Article  CAS  Google Scholar 

  5. Brod RD, Flynn HW, Clarkson JG, Pflugfelder SC, Culbertson WW, Miller D. Endogenous Candida endophthalmitis: management without intravenous amphotericin B. Ophthalmology. 1990;97(5):666–74.

    Article  CAS  PubMed  Google Scholar 

  6. Shao Y, Yu Y, Pei CG, Tan YH, Zhou Q, Yi JL, Gao GP. Therapeutic efficacy of intracameral amphotericin B injection for 60 patients with keratomycosis. Int J Ophthalmol. 2010;3(3):257.

    PubMed  PubMed Central  Google Scholar 

  7. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Survey Ophthalmol. 2009;54(3):372–400.

    Article  Google Scholar 

  8. Genentech. Avastin. Summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf (2010). Accessed Jul 2012.

  9. Novartis. Lucentis summary of product characteristics. Available at https://www.medicines.org.uk/emc/history/19409/SPC/Lucentis+10+mg+ml+solution+for+injection (2012). Accessed Jul 2012.

  10. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26(5):495–511.

    Article  PubMed  Google Scholar 

  11. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908.

    Article  Google Scholar 

  12. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–411.

    Article  PubMed  Google Scholar 

  13. Gerstenblith AT, Rabinowitz MP. The wills eye manual: office and emergency room diagnosis and treatment of eye disease. Philadelphia: Lippincott Williams & Wilkins; 2012.

    Google Scholar 

  14. McEvoy GK. AHFS drug information (2006). Bethesda, MD: American Society of Health System Pharmacists; 2006.

    Google Scholar 

  15. Montan PG, Wejde G, Setterquist H, Rylander M, Zetterström C. Prophylactic intracameral cefuroxime: evaluation of safety and kinetics in cataract surgery. J Catar Refract Surg. 2002;28(6):982–7.

    Article  Google Scholar 

  16. Ennis RD, Dahl TC. Stability of cidofovir in 0.9% sodium chloride injection for five days. Am J Health-Syst Pharm. 1997;54(19):2204–6.

    Article  CAS  PubMed  Google Scholar 

  17. Huq SM, Vazeen M. Cataract surgery and phacoemulsification for the beginning surgeons. Bloomington, IN: Author House; 2014.

    Google Scholar 

  18. Baum U, Peyman GA, Barza M. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv Ophthalmol. 1982;26(4):204–6.

    Article  CAS  PubMed  Google Scholar 

  19. Sobrin L, Kump LI, Foster CS. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina. 2007;27(7):952–7.

    Article  PubMed  Google Scholar 

  20. Soheilian M, Rafati N, Mohebbi MR, Yazdani S, Habibabadi HF, Feghhi M, et al. Prophylaxis of acute post traumatic bacterial endophthalmitis: a multicenter, randomized clinical trial of intraocular antibiotic injection, report 2. Archiv Ophthalmol. 2007;125(4):460–5.

    Article  CAS  Google Scholar 

  21. Graham RO, Peyman GA. Intravitreal injection of dexamethasone: treatment of experimentally induced endophthalmitis. Archiv Ophthalmol. 1974;92(2):149–54.

    Article  CAS  Google Scholar 

  22. Panel on opportunistic infections in HIV-infected adults and adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centres for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov.proxy.hsl.ucdenver.edu/contentfiles/lvguidelines/adult_oi.pdf. Accessed 27 Jan 2017.

  23. Diaz-Llopis M, España E, Muñoz G, Navea A, Chipont E, Cano J, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. British J Ophthalmol. 1994;78(2):120–4.

    Article  CAS  Google Scholar 

  24. Lieberman RM, Orellana J, Melton RC. Efficacy of intravitreal foscarnet in a patient with AIDS. N Engl J Med. 1994;330(12):868–9.

    Article  CAS  PubMed  Google Scholar 

  25. Arevalo JF, Garcia RA, Mendoza AJ. High-dose (5000-μg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela. Eur J Ophthalmol. 2005;15(5):610–8.

    Article  CAS  PubMed  Google Scholar 

  26. Teoh SC, Ou X, Lim TH. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen. Ophthalmology. 2012;119(3):588–95.

    Article  PubMed  Google Scholar 

  27. Trissel LA, Trissel LA. Handbook on injectable drugs. Bethesda: American Society of Health-System Pharmacists; 2007. p. 701–7.

    Google Scholar 

  28. McEvoy GK, editor. AHFS Drug Information 93. Bethesda: American Society of Health-System Pharmacists; 1993. p. 230–4.

    Google Scholar 

  29. McElhiney LF. Compounding guide for ophthalmic preparations. Washington, DC: American Pharmacists Association; 2013.

    Google Scholar 

  30. Lundy DC, Sidoti P, Winarko T, Minckler D, Heuer DK. Intracameral tissue plasmmogen activator after glaucoma surgery: indications, effectiveness, and complications. Ophthalmology. 1996;103(2):274–82.

    Article  CAS  PubMed  Google Scholar 

  31. Siatiri H, Beheshtnezhad AH, Asghari H, Siatirit N, Moghimi S, Piri N. Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery. British J Ophthalmol. 2005;89(11):1458–61.

    Article  CAS  Google Scholar 

  32. Tripathi RC, Park JK, Tripathi BJ, Millard CB. Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance. Am J Ophthalmol. 1988;106(6):719–22.

    Article  CAS  PubMed  Google Scholar 

  33. Yoshitomi F, Utsumi E, Hayashi M, Futenma M, Yamada R, Yamada S. Postoperative fluctuations of tissue plasminogen activator (t-PA) in aqueous humor of pseudophakes. J Catar Refract Surg. 1991;17(5):543–6.

    Article  CAS  Google Scholar 

  34. Wedrich A, Menapace R, Ries E, Polzer I. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. J Catar Refract Surg. 1997;23(6):873–7.

    Article  CAS  Google Scholar 

  35. Zalta AH, Sweeney CP, Zalta AK, Kaufman AH. Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants. Archiv Ophthalmol. 2002;120(11):1487–93.

    Article  Google Scholar 

  36. Bhadange Y, Shah B, Takkar B, Sinha R. Review of doses of important drugs in ophthalmology. Delhi J Ophthalmol. 2011;21(3):23–7.

    Google Scholar 

  37. John B. Intravitreal injections. Kerala J Ophthalmol. 2007;46.

    Google Scholar 

  38. Prakash G, Sharma N, Goel M, Titiyal JS, Vajpayee RB. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol. 2008;146(1):56–9.

    Article  PubMed  Google Scholar 

  39. Haddad RS, El-Mollayess GM. Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis. Middle East Afr J Ophthalmol. 2012;19(2):265.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Senior Drug Safety Specialist, Pharmacovigilance Department, Saudi Food and Drug Authority, Riyadh, Saudi Arabia

    Eman Ali Saeed Alghamdi

  2. Consultant of Cornea, Cataract and Refractive Surgery, Ophthalmology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia

    Abdulmalik Yahya Al Qahtani

  3. Senior Consultant Ophthalmic Surgeon, Dr. Mazen Sinjab Eye Clinic, Medcare Hospital, Dubai, United Arab Emirates

    Mazen M. Sinjab

  4. Consultant Clinical Pharmacist, Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia

    Khalid Mohammed Alyahya

Authors
  1. Eman Ali Saeed Alghamdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdulmalik Yahya Al Qahtani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mazen M. Sinjab
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Khalid Mohammed Alyahya
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Alghamdi, E.A.S., Al Qahtani, A.Y., Sinjab, M.M., Alyahya, K.M. (2020). Formulations of Extemporaneous Intraocular Injections. In: Extemporaneous Ophthalmic Preparations. Springer, Cham. https://doi.org/10.1007/978-3-030-27492-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27492-4_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27491-7

  • Online ISBN: 978-3-030-27492-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation